AEON Biopharma, Inc. (NASDAQ:AEON - Free Report) - Stock analysts at HC Wainwright upped their Q1 2024 earnings per share estimates for AEON Biopharma in a report released on Wednesday, April 17th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings of ($0.31) per share for the quarter, up from their prior estimate of ($0.39). HC Wainwright currently has a "Buy" rating and a $18.00 target price on the stock. The consensus estimate for AEON Biopharma's current full-year earnings is ($1.54) per share. HC Wainwright also issued estimates for AEON Biopharma's Q2 2024 earnings at ($0.31) EPS, Q3 2024 earnings at ($0.32) EPS, Q4 2024 earnings at ($0.24) EPS, FY2024 earnings at ($1.18) EPS and FY2025 earnings at ($1.16) EPS.
AEON Biopharma Trading Down 28.7 %
AEON traded down $1.88 on Friday, hitting $4.66. 108,634 shares of the company were exchanged, compared to its average volume of 52,754. AEON Biopharma has a twelve month low of $3.37 and a twelve month high of $17.17. The firm has a 50-day moving average price of $10.55 and a two-hundred day moving average price of $7.77.
AEON Biopharma (NASDAQ:AEON - Get Free Report) last released its earnings results on Friday, March 29th. The company reported ($0.71) EPS for the quarter.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the stock. Atalaya Capital Management LP purchased a new stake in AEON Biopharma during the 3rd quarter worth about $19,827,000. Vanguard Group Inc. lifted its holdings in AEON Biopharma by 8.3% during the 4th quarter. Vanguard Group Inc. now owns 209,785 shares of the company's stock worth $1,510,000 after buying an additional 16,091 shares during the last quarter. Formidable Asset Management LLC purchased a new stake in AEON Biopharma during the 3rd quarter worth about $360,000. Finally, Northern Trust Corp lifted its holdings in AEON Biopharma by 53.4% during the 4th quarter. Northern Trust Corp now owns 49,819 shares of the company's stock worth $359,000 after buying an additional 17,341 shares during the last quarter. 22.78% of the stock is owned by institutional investors and hedge funds.
About AEON Biopharma
(
Get Free Report)
AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.
Read More
Before you consider AEON Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AEON Biopharma wasn't on the list.
While AEON Biopharma currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
